Literature DB >> 6311321

Sultamicillin in the treatment of gonorrhoea caused by penicillin sensitive and penicillinase producing strains of Neisseria gonorrhoeae.

W A Atia, A M Emmerson, D Holmes.   

Abstract

A single oral dose of 2 g of sultamicillin and 1 g of probenecid was effective in the treatment of men with uncomplicated gonococcal urethritis caused by both penicillin sensitive strains of Neisseria gonorrhoeae and penicillinase producing strains of N gonorrhoeae (PPNG). Of 94 infected men who attended for at least one follow up examination, 91 (97%) were cured. The remaining three (3%) patients were still infected at follow up. Two of these patients had been re-exposed to an infected partner and were considered to be possible reinfections, while the third was deemed a treatment failure. Six of the 94 patients were infected with PPNG strains and all were successfully treated. Plasmid analysis of the PPNG strains showed Asian and African types both with and without transfer plasmid.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6311321      PMCID: PMC1046211          DOI: 10.1136/sti.59.5.293

Source DB:  PubMed          Journal:  Br J Vener Dis        ISSN: 0007-134X


  15 in total

1.  In-vitro activity of twelve antibacterial agents against Neisseria gonorrhoeae.

Authors:  I Phillips; M Ridley; D Rimmer; R Lynn
Journal:  Lancet       Date:  1970-02-07       Impact factor: 79.321

2.  Penicillinase-producing gonococci in Britain.

Authors:  A E Jephcott; N Dickgiesser; A N McClean
Journal:  Lancet       Date:  1981-08-01       Impact factor: 79.321

3.  Spectinomycin-resistant penicillinase-producing Neisseria gonorrhoeae.

Authors:  W A Ashford; D W Potts; H J Adams; J C English; S R Johnson; J W Biddle; C Thornsberry; H W Jaffe
Journal:  Lancet       Date:  1981-11-07       Impact factor: 79.321

4.  Emergence in the Netherlands of penicillinase-producing gonococci carrying "Africa" plasmid in combination with transfer plasmid.

Authors:  J D van Embden; B van Klingeren; M Dessens-Kroon; L J van Wijngaarden
Journal:  Lancet       Date:  1981-04-25       Impact factor: 79.321

5.  Non-beta-lactamase producing Neisseria gonorrhorea highly resistant to penicillin.

Authors:  R Shtibel
Journal:  Lancet       Date:  1980-07-05       Impact factor: 79.321

6.  Treatment of gonorrhoea caused by beta-lactamase producing strain of Neisseria gonorrhoeae with cefotaxime.

Authors:  R C Slack; J B Bittiner; R Finch
Journal:  Lancet       Date:  1980-02-23       Impact factor: 79.321

7.  CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.

Authors:  A R English; J A Retsema; A E Girard; J E Lynch; W E Barth
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

8.  Penicillinase-producing Gonococci in Liverpool.

Authors:  A Percival; J Rowlands; J E Corkill; C D Alergant; O P Arya; E Rees; E H Annels
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

9.  Beta-lactamase-producing, penicillin-resistant gonococcus.

Authors:  I Phillips
Journal:  Lancet       Date:  1976-09-25       Impact factor: 79.321

10.  Diagnostic treatment and reporting criteria for gonorrhoea in sexually transmitted disease clinics in England and Wales. 2: treatment and reporting criteria.

Authors:  M W Adler
Journal:  Br J Vener Dis       Date:  1978-02
View more
  4 in total

1.  Single dose intramuscular sulbactam and ampicillin in treating acute uncomplicated gonorrhoea.

Authors:  E T Houang; P Reardon
Journal:  Genitourin Med       Date:  1985-06

2.  Pharmacokinetics of sulbactam and ampicillin following oral administration of sultamicillin with probenecid.

Authors:  A M Emmerson; D A Cox; L J Lees
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

3.  Two regimens of sultamicillin in treating uncomplicated gonorrhoea.

Authors:  C Farthing; R N Thin; S Smith; I Phillips
Journal:  Genitourin Med       Date:  1985-02

Review 4.  Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H A Friedel; D M Campoli-Richards; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.